By Invite-Only – Learning Executive Series – February 2023
February 15 @ 6:00 pm - 7:30 pm EST
Building the Right Learning Architecture
Learning Executive Series
Virtual Roundtable & Networking Mixer
February 15, 2023 / 6 – 7:30 PM ET
This event is part of the new LTEN Learning Executive Series, a yearlong professional networking and development experience specifically for learning executives. Learn more and request an invitation to this year’s cohort.
As educators in the life sciences space, we seek to provide knowledge and introduce skills. Ultimately, we provide the pathway that will lead to growth through behavior change. We have an abundance of technology, tools, and platforms to assist us with this mission. If done well, we strategically put these technologies together in such a way that it creates a learning architecture that promotes ease of access to learning, relevance, tracking, and shareability.
So, which learning technologies are right for your organization, and how do you make those determinations? How can you get buy-in so that engagement with these platforms and learning retention is high? What are the objectives you are trying to achieve, and which technology solutions will promote your ability to get there?
Join us on February 15th and take the opportunity to learn from your peers. Guest speaker, LTEN board member, and former executive director of training and development at Boehringer Ingelheim Pharmaceuticals will share the approach his team took to building the right learning technology architecture to help achieve their learning and development goals.
We’ll go beyond a single technology or platform, and dive into the various considerations he and his team took to identify and implement learning technologies, where they found success, and where they faced challenges.REGISTER
This event is by invitation only. The LTEN Learning Executive Series is developed for senior-level L&D executives, currently employed by a pharmaceutical, biotech, medical device, or diagnostics organization. ALL registrations are subject to approval.